67 Participants Needed

Spinal Stimulation for Depression

(MOSPID Trial)

GG
FR
Overseen ByFrancisco Romo-Nava, MD, PhD
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: University of Cincinnati
Must be taking: Antidepressants
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new treatment for major depressive disorder (MDD) using transcutaneous spinal direct current stimulation (tsDCS). The goal is to determine if stimulating specific spinal pathways can improve depression symptoms. Researchers aim to identify the optimal dose and its effects on brain signals associated with depression. Suitable participants have experienced a current episode of MDD for at least four weeks but not more than two years and are on stable antidepressant medication. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative treatment.

Will I have to stop taking my current medications?

The trial requires participants to be on a stable dose of an FDA-approved antidepressant for at least 8 weeks before joining. However, you cannot participate if you are using anticonvulsant medications, calcium channel blockers, or need chronic pain medication like NSAIDs and opiates.

What prior data suggests that this spinal stimulation technique is safe for treating depression?

Research has shown that transcutaneous spinal direct current stimulation (tsDCS) is generally safe. In over 18,000 sessions with both healthy individuals and those with neurological or mental health conditions, no serious health issues occurred. This indicates that participants did not experience major problems from the treatment.

Studies also indicate that tsDCS is well-tolerated. In trials involving individuals with chronic pain, participants managed the treatment without significant issues. These findings suggest that tsDCS is a promising and safe option for exploring new treatments for depression.12345

Why do researchers think this study treatment might be promising for depression?

Researchers are excited about transcutaneous spinal direct current stimulation (tsDCS) for treating depression because it offers a non-invasive approach, unlike traditional treatments like antidepressant medications and psychotherapy. This method involves applying a mild electrical current to the spinal cord, which could modulate neural pathways linked to mood regulation. Unlike medications, which can take weeks to become effective and often have side effects, tsDCS has the potential to provide quicker relief with fewer side effects. Additionally, this technique might benefit patients who haven't responded well to conventional treatments, offering a new avenue of hope for those with treatment-resistant depression.

What evidence suggests that transcutaneous spinal direct current stimulation might be an effective treatment for major depressive disorder?

Research has shown that a new method called transcutaneous spinal direct current stimulation (tsDCS) could help treat major depressive disorder (MDD). A small initial study found that tsDCS is safe, easy to handle, and may assist with MDD. Early results suggest that tsDCS can change how certain brain areas process signals from the body, potentially improving depression symptoms. Other studies indicate that similar types of stimulation can reduce depression symptoms and work well with medications. In this trial, participants will receive different active doses of tsDCS or a sham treatment to evaluate its effectiveness. Overall, tsDCS presents a promising new option for people with MDD.56789

Who Is on the Research Team?

FR

Francisco Romo-Nava, MD, PhD

Principal Investigator

Lindner Center of Hope/ University of Cincinnati

Are You a Good Fit for This Trial?

This trial is for adults with Major Depressive Disorder (MDD) who may benefit from a non-invasive treatment. Participants should be interested in exploring new therapeutic options that involve spinal cord stimulation to manage their depression symptoms.

Inclusion Criteria

My mental health treatment has been stable for over 4 weeks.
I can do tasks required by the study.
Using an effective contraceptive method for participants with childbearing potential
See 6 more

Exclusion Criteria

My blood pressure is stable and not above 150/95 mmHg.
Any other relevant clinical reason as judged by the clinician
My IQ is suspected to be below 80.
See 15 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive transcutaneous spinal direct current stimulation (tsDCS) to evaluate spinal and brain-based SIPs target engagement markers in MDD

5 weeks
Multiple visits for tsDCS sessions and assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Transcutaneous Spinal Direct Current Stimulation
Trial Overview The study tests if transcutaneous spinal direct current stimulation (tsDCS) can modulate bodily signals linked to MDD. It's a double-blind, crossover, sham-controlled study where participants receive different doses of tsDCS to see how it affects brain activity related to depression.
How Is the Trial Designed?
4Treatment groups
Active Control
Placebo Group
Group I: 3.0 ActiveActive Control1 Intervention
Group II: 3.5 ActiveActive Control1 Intervention
Group III: 2.5 ActiveActive Control1 Intervention
Group IV: 2.0 ShamPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Cincinnati

Lead Sponsor

Trials
442
Recruited
639,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials
3,007
Recruited
2,852,000+

Published Research Related to This Trial

Transcutaneous spinal direct current stimulation (tsDCS) can modulate corticospinal excitability in individuals with chronic incomplete spinal cord injury, showing trends of increased excitability on one side and decreased on the other, depending on the stimulation polarity.
In a study with six participants, no significant differences were found between stimulation conditions, but the results suggest that further research is needed to optimize electrode placement and explore the potential for improved movement function.
The effect of transcutaneous spinal direct current stimulation on corticospinal excitability in chronic incomplete spinal cord injury.Powell, ES., Carrico, C., Salyers, E., et al.[2018]
Anodal transcutaneous spinal direct current stimulation (tsDCS) significantly increased the temporal summation threshold of the nociceptive withdrawal reflex in 10 healthy subjects, indicating its potential to modulate spinal cord pain pathways.
This stimulation also led to a decrease in the perception of pain, suggesting that anodal tsDCS could be an effective non-invasive treatment for clinical pain conditions related to spinal cord activity.
Modulation of temporal summation threshold of the nociceptive withdrawal reflex by transcutaneous spinal direct current stimulation in humans.Perrotta, A., Bolla, M., Anastasio, MG., et al.[2017]
Trans-spinal direct current stimulation (tsDCS) has shown potential benefits, such as reducing hypertonia and neuropathic pain, particularly with anodal stimulation in patients with central nervous system diseases, based on a review of 8 studies involving 143 subjects.
The application of tsDCS was found to be feasible and safe, with no severe adverse effects reported, although the overall effectiveness remains uncertain due to variability in study results and the need for further research.
Trans-Spinal Direct Current Stimulation in Neurological Disorders: A systematic review.Fernández-Pérez, JJ., Serrano-Muñoz, D., Beltran-Alacreu, H., et al.[2023]

Citations

Effects of Transcranial Direct Current Stimulation on pain and ...tDCS appears to decrease pain intensity and modulate thresholds for pressure and heat pain, as well as enhance tolerance to heat and cold.
Effects of Transcutaneous Spinal Direct Current Stimulation ...Our results demonstrated that the use of tsDCS for chronic pain subjects is safe and feasible. All subjects tolerated the stimulation well ...
Transcranial direct current stimulation in treatment resistant ...Scores on the Hamilton Depression Rating Scale were reduced from baseline by 14.7% for active tDCS and 10% for placebo tDCS. In contrast, subjective mood ...
Effect of non-invasive spinal cord stimulation in ...The results from this pilot study suggest that tsDCS is feasible, well-tolerated, and shows therapeutic potential in MDD.
Transcranial direct current stimulation as an adjuvant in the ...Transcranial direct current stimulation is an effective therapeutic option in the reduction of depressive symptoms as an adjunct to pharmacological treatment.
Safety of transcranial Direct Current Stimulation: Evidence ...To date, the use of conventional tDCS protocols in human trials (≤40 min, ≤4 mA, ≤7.2 Coulombs) has not produced any reports of a Serious Adverse Effect or ...
Effects of Transcranial Direct Current Stimulation on pain ...Conclusions: Our findings suggest that tDCS might be effective for fibromyalgia, migraine, and neuropathic pain associated with spinal cord ...
Effects of cervical transcutaneous spinal direct current ...No serious adverse events have been reported so far in over 18,000 sessions administered to healthy participants, neurological and psychiatric patients.
Effects of Transcutaneous Spinal Direct Current Stimulation ...Our results demonstrated that the use of tsDCS for chronic pain subjects is safe and feasible. All subjects tolerated the stimulation well ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security